Novartis vs Bayer
A reminder to always substantiate claims in pharma ads
Brexit: International marks, unregistered designs and more
par Louise Popple
Major step forward for the Unified Patent Court
par Dr. Gisbert Hohagen, Lic. en droit (Paris II/ Assas) et Dr. Philipp Krusemarck
"Bait and switch" selling: when is it OK to sell competing products?
par Louise Popple
Commission reveals new IP Action Plan: Changes for designs, GIs, data and more
par Alice Anderson et Louise Popple
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
par Alison Dennis et Dr Paul England
Reloaded: How UK supplementary protection certificates will change from 1 January 2021
par Dr Paul England
Russian coronavirus vaccine – approval process in Hungary and the EU
Available in Hungarian
Pharmaceutical patent law in times of crisis: A comparative study – Part 2
par plusieurs auteurs
Plus ça change? How UK patents will be affected from 1 January 2021
par Dr Paul England
Why developments in global trade will highlight patent enforcement in the UK and Trans-Pacific countries
par plusieurs auteurs
Pharmaceutical patent law in times of crisis: A comparative study – Part 1
par plusieurs auteurs